GlassScriptPhysician profile
David Shibata
NPI 1700892387
$1,136.28
in general payments reported to CMS, 2019-2025
11 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2021: $21.26 · 2023: $93.74 · 2024: $427 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $431 · Food and Beverage: $267 · Travel and Lodging: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $431.35 |
| Food and Beverage | $266.87 |
| Travel and Lodging | $133.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $406.41 | 2024-2025 | |
| Taiho Oncology, INC. | $161.31 | 2025 | |
| Genentech USA, INC. | $125.45 | 2019 | |
| Intuitive Surgical, INC. | $122.36 | 2019 | |
| Tempus Ai, INC | $105.79 | 2024-2025 | Xt Cdx |
| Medtronic, INC. | $80.90 | 2023-2024 | Signia |
| Integra Lifesciences Corporation | $48.66 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| E.R. Squibb & Sons, L.L.C. | $35.28 | 2019 | |
| Acera Surgical, INC. | $21.26 | 2021 | |
| Acrotech Biopharma INC. | $15.41 | 2024 | Beleodaq |
| Ambu INC. | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shibata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.